臨床材料より分離された各種病原細菌に対するgatifloxacinの抗菌力について Comparative antibacterial activity of gatifloxacin against clinical isolates

この論文にアクセスする

この論文をさがす

著者

抄録

最近開発された新キノロン系薬gatifloxacin (GFLX) の抗菌力を1990年より1995年までに分離された臨床分離株2, 178株について測定し, sparfloxacin (SPFX), tosufloxacin (TFLX), ofloxacin (OFLX), ciprofloxacin (CPFX), norfloxacin (NFLX) などの抗菌力と比較検討した。<BR>GFLXはグラム陽性菌, 陰性菌に対し強い抗菌力を示し, その抗菌スペクトルはSPFX, TFLXにほぼ等しく, NFLX, OFLXよりも優れていた。特に<I>Streptococcus</I>属 (ペニシリン耐性<I>Streptococcus pneumoniae</I>を含む) や<I>Enterococcus</I>属 (<I>Enterococcus faecalis, Enterococcus faecium</I>を除く), <I>Haemophilus influenzae</I> (ampicillin耐性株を含む), <I>Branhamella catarrhalis</I>に対しては強力であった。<BR>GFLXの抗菌力は<I>Bacteroides thetaiotaomicron, Prevotella bivia, Fusobacterium</I> spp.には他の同系統の抗菌薬と同様弱かった。

Gatifloxacin (GFLX) is a newly synthesized 6-fluoro-8-methoxy quinolone with a wide spectrum of antibacterial activity against various bacteria. The <I>in vitro</I> activity of GFLX was compared with that of sparfloxacin (SPFX), tosufloxacin (TFLX), ofloxacin (GFLX), and norfloxacin (NFLX), against 2, 178 strains, including streptococci (<I>S.pyogenes, S.agalactiae, S.intermedius</I>, group C and Gstreptococci, and <I>S.pneumoniae</I>), enterococci (<I>E.faecalis, E.faecium</I> and others), <I>Branhamella catarralis, Haemophilus influenzae, Helicobacter pylori, Gardnerella vaginalis, Serratia marcescens, Enterobacter</I> (<I>E.cloacae</I> and <I>E.aerogenes</I>), <I>Pseudomonas aeruginosa</I>, and anaerobes (<I>Peptostreptococcus</I> spp., <I>Lactobacillus</I> spp., <I>Propionibacterium acnes, Eubacterium</I> spp., <I>Clostridium</I> (<I>C. perfringens</I> and <I>C.difficile</I>), <I>Veillonella, Bacteroides fragilis</I> group, and other Gram-negative bacilli), which had been isolated from clinical materials during the period 1990 to 1995.<BR>GFLX showed a broad spectrum of antibacterial activity against Gram-positive and Gramnegative bacteria, and its activity was almost equal to that of SPFX and TFLX, and superior to that of OFLX and NFLX. GFLX was especially potent against β-haemolytic streptococci, penicillin-resistant <I>Streptococcus pneumoniae</I>, enterococci (except for <I>Enterococcus faecalis</I> and <I>Enterococcus faecium</I>), and <I>Haemophilus influenzae</I> (including ampicillin-resistant strains).<BR>The antibacterial activity of GFLX was weak against <I>Bacteroides thetaiotaomicron, Prevotella bivia</I>, and <I>Fusobacterium</I> spp.

収録刊行物

  • 日本化学療法学会雜誌 = Japanese journal of chemotherapy

    日本化学療法学会雜誌 = Japanese journal of chemotherapy 47, 57-68, 1999-09-27

    Japanese Society of Chemotherapy

参考文献:  31件中 1-31件 を表示

被引用文献:  5件中 1-5件 を表示

各種コード

ページトップへ